General information


7th Annual Sickle Cell and Thalassaemia: Advanced Conference

3rd - 5th October 2013



DOWNLOAD THE COURSE BROCHURE                                                                                                 

The conference will be held jointly at Evelina Children’s Hospital and St Thomas’ Hospital, London


Who should attend?

This three day conference is aimed at all those with a common interest in sickle cell and thalassaemia, including Specialist Registrars, Consultant Haematologists, Paediatricians and Clinical Nurse Specialists.

For the purposes of CPD, the Conference has been approved by The Royal College of Pathologists for 15 CPD points.

Course director

Dr Baba Inusa, Consultant Paediatrician (Haematology)

Dr Inusa completed his general paediatric training, along with further training in haematology at the Hammersmith Hospital, London and Guys and Kings College Hospitals, London.

He has been a Consultant for the last 16 years combining roles as a paediatrician with specialist responsibility for sickle cell and thalassaemia.

Overall aims and objectives

This conference is intended to update those who are working with patients across the world with SCD, to consider the most efficient and safe way to manage these vulnerable patients.


This course combines interactive lectures, case studies, examples of good practice, group work and Q & A sessions.

Course materials

Delegates will receive comprehensive course materials to take away



Thursday 3rd October 2013:  Start 09:00, finish: 17:30. Evening reception 18:00 

Friday 4th October 2013:       Start 09:00, finish: 17:30 and networking

Saturday 5th October 2013:   Start 08:30, finish: 16:00 approx.

Overview of programme

This programme will provide participants with an overview of the key issues in sickle cell disease including a look at the pathology of SCD, diagnostic testing, the impact of environmental factors and genetic modifiers on disease severity, managing acute and chronic sickle cell crises, and dealing with major complications in patients including stroke, renal, liver and cardiac problems and the treatment options available.

It will discuss how to manage the transition from paediatric to adulthood, preventing morbidity and mortality and the latest research in SCD.

Finally it will cover thalassaemia issues and common management issues for SCD, Thal-Chelation therapy and Stem cell transplantation.

Key issues covered include:

Sickle Cell Disease: Overview

  • Setting the Agenda: a summary of the key issues in haemoglobinopathies
  • Genetic diagnosis in haemoglobinopathies
  • Pathological Features of Sickle Cell Disease
  • Severe Sickle Cell Disease – diagnosis and treatment
  • Pulmonary Hypertension in children with Sickle Cell Disease
  • Lung Disorders in Sickle Cell Disease
  • Cardiac disorders in haemoglobinapthies
  • Renal Disorders in Sickle Cell Disease
  • Respiratory Management
  • Neuroimaging studies in Sickle Cell Disease

Thalassaemia: Overview

  • Setting the Agenda: a summary of the key issues in Thalassaemia
  • Thalassaemia: Diagnosis and Treatment
  • Pathological Features of Thalassaemia
  • Genetic diagnosis
  • Common emergencies in Thalassaemia
  • Therapeutic Intervention
  • Endocrine and metabolic bone disorders
  • Management of iron overload in Thalassaemia
  • Infectious diseases in developing countries
  • Global Research Update

Public Health Agenda

  • Psychosocial and Public Health Perspectives in Haemoglobinopathies
  • Cultural Variations
  • Models for Counselling Services


  • Obstetrics issues in Sickle Cell and Thalassaemia
  • Newborn Outcomes: clinical and governance issues
  • Transition: From Paediatrics to Adults

Sponsors and exhibitors

Terumo BCT

A global leader in blood component, therapeutic apheresis and cellular technologies, Terumo BCT is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction coupled with leading technologies in therapeutic apheresis and cell processing.
Through our efforts in therapeutic apheresis and cell collections, Terumo BCT is committed to advancing apheresis. By collaborating with customers, Terumo BCT is enabling the best possible procedures today, increasing the number of clinicians adopting these procedures, identifying new uses and developing next-generation procedures.


Terumo BCT logo



Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on inflammation and genetic diseases, with three late stage biological development projects within hemophilia and neonatology. We also market a portfolio of specialty and rare disease products for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing.

SOBI logo


Novartis Pharma AG

We would like to thank Novartis Pharma AG for supporting the Sickle Cell and Thalassaemia Advanced Conference 2013 through an unrestricted educational grant.




  • Consultants (3 days)          £330
  • Non-consultant (3 days)     £250
  • Daily rate (1 day)               £115





We are pleased to be able to offer a small number of bursaries this year. These will take the form of a reduction in the course fee.

These bursaries are generally aimed at those who would otherwise have difficulty meeting the course fees.

Applicants will be assessed on a case by case basis.

Application for a bursary should be made using the BURSARY APPLICATION FORM

Abstract session

If you would like to submit an abstract, please refer to the following ABSTRACT GUIDELINES.

Deadline for abstract submission is 30th August 2013.


Contact us

If you have any enquiries about the course, please contact:

Ian Mackie

Events Organiser

Guys and St Thomas’

Tel: + 44 (0) 207 188 1622